Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Prialt Clears FDA, Will Launch In Late January

This article was originally published in The Pink Sheet Daily

Executive Summary

Intrathecal therapy is indicated for "the management of severe chronic pain in patients…who are intolerant or refractory to other treatment." Elan will promote the non-opioid therapy with 40 to 50 sales reps targeting 3,000 doctors.

You may also be interested in...



Overly Aggressive Prialt Dose Data Are Not Surrogate Endpoints, FDA Says

Elan had proposed accelerated approval of the intractable pain therapy in lieu of an agency-requested third pivotal trial, agency review documents show.

Overly Aggressive Prialt Dose Data Are Not Surrogate Endpoints, FDA Says

Elan had proposed accelerated approval of the intractable pain therapy in lieu of an agency-requested third pivotal trial, agency review documents show.

Biogen Idec Shifting Tysabri Sales Force To Avonex Detail

Biogen Idec will shift the focus of its Tysabri sales force to Avonex promotion following the marketing suspension of the newer multiple sclerosis agent, the company said

Related Content

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel